97228 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
IMMUNOGLOBULIN VARIABLE DOMAINS
#2PROCESS OF PURIFICATION OF PROTEIN
#3USES OF OMALIZUMAB
#4PROCESS OF PURIFICATION OF PROTEIN
#5PROCESS OF PURIFICATION OF PROTEIN
#6BISPECIFIC ANTIBODIES AND CONSTRUCTS FOR LYSOSOMAL TARGETING DEGRADATION AND METHODS OF USE THEREOF
#7ISOLATED ANTIGEN BINDING PROTEIN AND USE THEREOF
#8Fc VARIANTS WITH ALTERED BINDING TO FcRn
#9VARIANT FC REGIONS
#10VARIANT FC REGIONS
#11ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND IGE
#12ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND IGE
#13ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND IGE
#14PROCESS OF PURIFICATION OF PROTEIN
#15TREATMENT OF ALLERGIC REACTIONS USING ANTI-IGE ANTIBODIES
#16AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN
#17AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN
#18PROCESS OF PURIFICATION OF PROTEIN
#19Fc VARIANTS WITH ALTERED BINDING TO FcRn
#20RETROVIRAL-LIKE PARTICLE-REDUCED CHINESE HAMSTER OVARY PRODUCTION CELL LINES
#21ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
#22DISPLACERS OF IGE-FCERI
#23IgE BINDING PROTEINS AND USES THEREOF
#24Method for Primary Prevention of Allergic Disorders During Infancy Through IgE-Class-Specific Immunosuppression
#25PROCESS OF AFFINITY CHROMATOGRAPHY
#26FORMULATION OF HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODY
#27METHOD AND APPARATUS FOR USING OMALIZUMAB
#28METHOD AND APPARATUS FOR USING OMALIZUMAB
#29METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB
#30IgE binding proteins and uses thereof
#31ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
#32ANTI-IgE ANTIBODIES
#33PROCESS OF PURIFICATION OF PROTEIN
#34INHALER SYSTEM
#35INHALER SYSTEM
#36Fc VARIANTS WITH ALTERED BINDING TO FcRn
#37MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
#38PROCESS FOR IMPROVING POLYPEPTIDE EXPRESSION IN MAMMALIAN CELL CULTURE
#39BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES
#40PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY
#41Fc VARIANTS WITH ALTERED BINDING TO FcRn
#42Process of purification of protein
#43TREATMENT OF PEANUT ALLERGY WITH TOLERIZING NANOPARTICLES
#44HIGH CONCENTRATION ANTIBODY FORMULATIONS
#45ANTI-IGE ANTIBODIES
#46ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO PLURALITY OF ANTIGEN MOLECULES REPEATEDLY
#47PROCESS OF PURIFICATION OF PROTEIN
#48Method for Primary Prevention of Allergic Disorders During Infancy Through IgE-Class-Specific Immunosuppression
#49FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE
#50CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS
#51MODIFIED IMMUNOGLOBULIN WITH AFFINITY FOR FcGAMMARIIb AND METHOD OF USE THEREOF
#52HYDROXYPROPYL METHYL CELLULOSE DERIVATIVES TO STABILIZE POLYPEPTIDES
#53AN IMPROVED PROCESS OF STORING AND PREPARING THE PROTEIN
#54SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES
#55CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS
#56NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
#57PEPTIDE IMMUNOGENS AND FORMULATIONS THEREOF TARGETING MEMBRANE-BOUND IgE FOR TREATMENT OF IgE MEDIATED ALLERGIC DISEASES
#58ANTI-IGE ENGINEERED ANTIBODY AND APPLICATION THEREOF
#59TREATMENT OF FOOD ALLERGY USING ANTI-IGE ANTIBODIES
#60Methods and compositions for antibody to high affinity receptor for IgE
#61AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN
#62AN IMPROVED PROCESS OF AFFINITY CHROMATOGRAPHY
#63AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN
#64LUCIFERASE LINKED IMMUNOSORBENT ASSAY
#65METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IGM RESPONSES
#66TREATMENT OF IGE-MEDIATED DISEASES
#67Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof
#68Process for concentration of antibodies and therapeutic products thereof
#69Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#70Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#71ADOPTIVE T-CELL THERAPY USING EMPD-SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR TREATING lgE-MEDIATED ALLERGIC DISEASES
#72Inhaler system
#73Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof
#74METHODS OF TREATMENT USING OMALIZUMAB
#75IMMUNOGLOBULIN VARIABLE DOMAINS
#76IMMUNOGLOBULIN VARIABLE DOMAINS
#77ANTI-IgE CONSTRUCT
#78Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#79EXCIPIENT FOR BIOTHERAPEUTICS
#80Fc VARIANTS WITH ALTERED BINDING TO FcRn
#81COMPOSITIONS AND METHODS FOR TREATING ECZEMA
#82FORMULATION OF HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODY
#83Immunoglobulin variable domains
#84Anti-IgE antibodies
#85Mass Spectrometry Calibrator
#86Treatment of allergic diseases with chimeric protein
#87T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
#88METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG
#89ANTI-IgE ANTIBODIES
#90Immunoglobulin variable domains
#91Immunoglobulin variable domains
#92METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY
#93Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#94Anti-IgE antibody specifically binding to membrane-bound IgE antibody of IgE antibody-producing B cells and method for diagnosing and treating allergic symptoms using the same
#95Conjugates of biologically active molecules to functionalized polymers
#96Fc variants with altered binding to FcRn
#97Immunoglobulin variable domains
#98Immunoglobulin variable domains
#99Immunoglobulin variable domains
#100Formulations of biological polymers for oral administration
#101METHODS AND AGENTS FOR TREATING ORGAN INJURY AND TRANSPLANT REJECTION
#102COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS
#103Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#104Production of T cell retargeting hetero-dimeric immunoglobulins
#105TARGETED DELIVERY METHODS AND COMPOSITIONS FOR ANTIHISTAMINES
#106Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#107FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE
#108METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB
#109Fc VARIANTS WITH ALTERED BINDING TO FcRn
#110Inhaler system
#111PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
#112Immunoglobulin variable domains
#113Anti-NGF Antibodies for Treatment of Various Disorders
#114Stable Dual Variable Domain Immunoglobulin Protein Formulations
#115THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES
#116Inhaler system
#117Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#118Compositions and methods for treating IgE-mediated disorders
#119Fc VARIANTS WITH ALTERED BINDING TO FcRn
#120STABILIZED PROTEIN GEL PREPARATION
#121Fc VARIANTS WITH ALTERED BINDING TO FcRn
#122Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression
#123Immunoglobulin variable domains
#124Conjugates of biologically active molecules to functionalized polymers
#125MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES
#126Methods of neutralizing IL-8 biological activity
#127METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS
#128PROTEIN AQUEOUS SUSPENSION PREPARATION
#129T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
#130CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#131ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
#132COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS
#133Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#134HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
#135Therapeutic anti-IgE antibodies and methods and compositions thereof
#136Compositions and methods for treating eczema
#137AFFINITY LIGANDS AND METHODS RELATING THERETO
#138REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
#139Drug containing carrier into cell for forming immune complex
#140Anti-IgE antibodies
#141METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IGM RESPONSES
#142Conjugates of biologically active molecules to functionalized polymers
#143Methods for reducing toxicity of a chemotherapeutic drug
#144Methods for Suppressing Allergic Reactions
#145METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS
#146Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#147Production of T cell retargeting hetero-dimeric immunoglobulins
#148Compositions and methods for treating or preventing lupus
#149OMALIZUMAB RESISTANT IGE VARIANTS AND THEIR USE IN ANTI-IGE THERAPY
#150Nucleic acids encoding IL-8 antibodies
#151Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
#152Treatment of allergic diseases with chimeric protein
#153Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#154RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
#155VACCINES FOR THE TREATMENT AND PREVENTION OF IGE MEDIATED DISEASES
#156Targeted delivery methods and compositions for antihistamines
#157T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
#158Methods for suppressing allergic reactions
#159Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
#160Methods for allergy diagnosis
#161METHODS AND COMPOSITIONS FOR SUPPRESSING IGE-MEDIATED ANAPHYLAXIS
#162NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
#163Antibodies that bind activatable antibodies and methods of use thereof
#164Compositions and methods for treating or preventing lupus
#165COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS
#166HUMAN ANTIBODIES AND PROTEINS
#167Methods for producing recombinant glycoproteins with modified glycosylation
#168Production of T cell retargeting hetero-dimeric immunoglobulins
#169Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells
#170Immunoglobulin variable domains
#171METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS
#172ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#173HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
#174Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#175Affinity ligands and methods relating thereto
#176Optimized Fc variants and methods for their generation
#177Optimized Fc variants and methods for their generation
#178Gene therapy to prevent reactions to allergens
#179Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#180Anti-dog IgE monoclonal antibody, and light-chain variable region and heavy-chain variable region of anti-dog IgE monoclonal antibody
#181METHOD AND APPARATUS FOR MAKING COMPOSITIONS FOR PULMONARY ADMINISTRATION
#182IL-8 antibodies
#183Anti-immunoglobulin E antibodies and methods of using thereof
#184Mutated parvovirus structural proteins as vaccines
#185CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#186Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa
#187Antibodies specific to a novel epitope on CεMX of human membrane-bound IgE and uses thereof in treating IgE-mediated diseases
#188Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
#189ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
#190Methods for producing recombinant glycoproteins with modified glycosylation
#191Methods and compositions for suppressing IgE-mediated anaphylaxis
#192METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
#193High concentration antibody and protein formulations
#194Method for identifying compounds of therapeutic interest
#195GLYCOPROTEIN
#196IgE peptide vaccine
#197Fc variants with altered binding to FcRn
#198Antibodies that bind activatable antibodies and methods of use thereof
#199Conjugates of biologically active molecules to functionalized polymers
#200METHODS RELATED TO OMALIZUMAB
#201Compositions and methods for treating IgE-mediated disorders
#202Production of T cell retargeting hetero-dimeric immunoglobulins
#203IgE CH3 peptide vaccine
#204Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
#205Compositions and methods for treating IgE-mediated disorders
#206Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
#207Optimized Fc variants and methods for their generation
#208DRUG CONTAINING CARRIER INTO CELL FOR FORMING IMMUNE COMPLEX
#209Reduced-viscosity concentrated protein formulations
#210HUMAN ANTIBODIES AND PROTEINS
#211HUMAN ANTIBODIES AND PROTEINS
#212Treatment of allergic diseases with recombinant antibodies
#213Process for concentration of antibodies and therapeutic products thereof
#214Methods of treating atherosclerosis and aneurysm
#215Methods for suppressing allergic reactions
#216High affinity, anti-human IgE antibodies
#217Methods for treating chronic obstructive pulmonary disease
#218Methods for optimizing domain stability of binding proteins
#219C(epsilon)mX peptides for inducing immune responses to human mIgE on B lymphocytes
#220Rapid clearance of antigen complexes using novel antibodies
#221Binding Members For IgE Molecules
#222Compositions and methods for treating or preventing lupus
#223APOPTOTIC ANTI-IGE ANTIBODIES
#224Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
#225Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes
#226Optimized Fc variants and methods for their generation
#227ANTI-IGE ANTIBODIES AND METHODS USING SAME
#228Protein formulation
#229Compositions and methods for treating IgE-mediated disorders
#230Compositions and methods for treating IgE-mediated disorders
#231Compositions and methods for treating IgE-mediated disorders
#232Optimized Fc variants and methods for their generation
#233Optimized FC variants and methods for their generation
#234Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#235High affinity, anti-human IgE antibodies
#236ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#237STABILIZED SINGLE DOMAIN ANTIBODIES
#238CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#239Optimized Fc variants and methods for their generation
#240Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes
#241SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#242Polypeptide variants with altered effector function
#243POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
#244Nucleic acid encoding apoptotic anti-IgE antibodies
#245Methods of using apoptotic anti-IGE antibodies
#246Use of IgGimmunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
#247Apoptotic anti-IgE antibodies
#248TRANSGENIC ANIMALS EXPRESSING HUMAN IGE-M1'
#249Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
#250Fc variants that extend antibody half-life
#251Molecular Antigen Array
#252CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH
#253Fc variants with altered binding to FcRn
#254Reduced-viscosity concentrated protein formulations
#255Methods for treating chronic obstructive pulmonary disease
#256High concentration antibody and protein formulations
#257Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
#258METHODS FOR TREATMENT OF ALLERGIC ASTHMA
#259Molecular Antigen Array
#260IgE CH3 peptide vaccine
#261POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
#262Protein-based assays for screening of the IgE-receptor interaction
#263Anti-NGF antibodies for the treatment of various disorders
#264CDR-repaired antibodies
#265Protein Formulation
#266Anti-PCSK9 antibodies with pH dependent antigen binding
#267BINDING MEMBERS FOR IGE MOLECULES
#268IDENTIFICATION OF NOVEL IgE EPITOPES
#269SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR
#270SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#271METHOD OF ADMINISTERING THERAPEUTIC POLYPEPTIDES, AND POLYPEPTIDES THEREFOR
#272Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis
#273STABILIZED SINGLE DOMAIN ANTIBODIES
#274Methods and compositions for inhibiting binding of IgE to a high affinity receptor
#275SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR
#276Method for quantification of antigen-specific canine IgE
#277Fc variants with altered binding to FcRn
#278GLYCOPROTEIN COMPOSITIONS
#279Angiotensin peptide-carrier conjugates and uses thereof
#280ANTI IgE ANTIBODIES
#281High affinity, anti-human IgE antibodies
#282SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#283MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES
#284GLYCOPROTEIN COMPOSITIONS
#285ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#286Methods for treating Chronic Obstructive Pulmonary Disease
#287FC VARIANTS WITH ALTERED BINDING TO FCRN
#288Fc variants with altered binding to FcRn
#289Fc variants with altered binding to FcRn
#290Fc variants with altered binding to FcRn
#291FC variants with altered binding to FCRN
#292Fc variants with altered binding to FcRn
#293CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#294Polypeptide variants with altered effector function
#295PROTEIN FORMULATION
#296METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS
#297CROSS-SPECIES-SPECIFIC BINDING DOMAIN
#298Binding members for IgE molecules
#299Methods and compositions for inhibiting binding of IgE to a high affinity receptor
#300IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis